Drug Enhancement Company of America

MyClyns™ is the only readily accessible, non-alcohol, first response spray for healthcare givers and first responders who become acutely exposed to potentially harmful pathogens. 

Clinically effective product for the treatment of nausea in pregnant women. Large market with few prescription alternatives.

Oncology Product

Status : Discussion/Terms Sheet

A significant advancement in the administration of prescription nutritional supplements for women. Patent pending, this product offers some unique advantages over the competitive products in its class.

MyClyns™

Status : Commercialized

 

 

 

Anti-nausea Product

Status : Evaluation

 

 

Nutritional Product

Status : Evaluation

Selected Active Projects

Additional information on any DECA projects requires a signed confidentiality agreement.

DECA has been active in evaluating a package of oncology products, including one on the market, one in Phase III clinical trials and one in Phase II trials.

Other

DECA management has reviewed numerous products during 2006/2007 including : pain management, radioisotopes, attention deficit disorder, prenatal vitamins, cough & cold and gastrointestinals.